When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program-Reference-Cited by-同舟云学术

When Is Osteonecrosis Not Osteonecrosis?: Adjudication of Reported Serious Adverse Joint Events in the Tanezumab Clinical Development Program

Author:

Hochberg Marc C.¹,Tive Leslie A.²,Abramson Steven B.³,Vignon Eric⁴,Verburg Kenneth M.⁵,West Christine R.⁵,Smith Michael D.⁵,Hungerford David S.⁶

Affiliation:

1. University of Maryland School of Medicine; Baltimore

2. Pfizer Inc.; New York New York

3. New York University Medical Center; New York New York

4. Université Claude Bernard Lyon 1; Lyon France

5. Pfizer Inc.; Groton Connecticut

6. Johns Hopkins University School of Medicine, Johns Hopkins Hospital, and Good Samaritan Hospital; Baltimore Maryland

Funder

Pfizer Inc.

Publisher

Wiley

Subject

Immunology,Rheumatology,Immunology and Allergy

Link

Reference51 articles.

3. NGF as a mediator of inflammatory pain;McMahon;Philos Trans R Soc Lond B Biol Sci,1996

Cited by 129 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献